Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
Read more at Invest New Drugs Today!Read More ➞
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody for immunotherapy research
Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications http://www.ventana.com/site/page?view=press-release-aug25-2014Read More ➞
Introducing PTEN (SP218)!
New test for cancer researchers targets important tumor-suppressor protein Highly sensitive test gives researchers a more sophisticated tool to assess PTEN protein expression in cancer cells PLEASANTON, Ca., September 9, 2013 — As researchers push to develop more customized diagnostics and therapies for solid tumor cancers, they demand increasingly sensitive tests that offer reliable, reproducible […]Read More ➞
Spring Bioscience to Launch exclusive BRAF V600E Antibody to the Research Market
Ventana signs exclusive licensing agreement for the commercialization of a novel BRAF V600E mutation antibody for cancer detection New assay will strengthen leadership in emerging area of mutation-specific antibodies to address unmet medical needs in cancer Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the […]Read More ➞